1042 GMT - Novartis exceeded expectations with profit and sales figures, accompanied by an improved outlook, defying concerns about upcoming generic competition in the U.S. for three of its key products, Vontobel analyst Stefan Schneider says in a note. "With the generic entry to three Novartis products still expected per mid-year, the guidance increase appears to us as a very confident sign that the company's growth drivers are expected to perform well also during the remainder of the year," he says. The Swiss drugmaker hereby signals that it can comfortably overcompensate the expected generic erosion, he says. Shares rise 1.1% to 94.43 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 06:42 ET (10:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.